Literature DB >> 28986256

MicroRNA-7 inhibits cell proliferation of chronic myeloid leukemia and sensitizes it to imatinib in vitro.

Ming-Jie Jiang1, Juan-Juan Dai2, Dian-Na Gu1, Qian Huang3, Ling Tian4.   

Abstract

MicroRNA is a large class of non-coding small RNA that exerts critical roles in many physiological processes including cell proliferation. MicroRNA-7 (miR-7) has been considered as a tumor suppressor in most malignant tumors versus a tumor promoter in some other ones. However, its role in chronic myeloid leukemia remains unknown. Herein, we found that K562 cell proliferation was largely suppressed when it was stably transfected with miR-7. In accordance with that, apoptosis was also significantly upregulated in miR-7 stably-transfected K562 cells. Moreover, we found that miR-7-overexpressed K562 cells were far more sensitive to imatinib than controls. Further investigations showed that the ABL1 was a direct target of miR-7. Expression level of BCR-ABL and the activity of its downstream PI3K/AKT pathway were significantly reduced in miR-7-transfected cells. Taken together, our results showed that miR-7 inhibited proliferation and promoted apoptosis in K562 cells, and miR-7 might help to sensitize them to imatinib through BCR-ABL/PI3K/AKT signaling in chronic myeloid leukemia.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  BCR-ABL; Chronic myeloid leukemia; Imatinib; MicroRNA-7; Proliferation

Mesh:

Substances:

Year:  2017        PMID: 28986256     DOI: 10.1016/j.bbrc.2017.10.001

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  10 in total

1.  MicroRNA in combination with HER2-targeting drugs reduces breast cancer cell viability in vitro.

Authors:  Lisa Svartdal Normann; Miriam Ragle Aure; Suvi-Katri Leivonen; Mads Haugland Haugen; Vesa Hongisto; Vessela N Kristensen; Gunhild Mari Mælandsmo; Kristine Kleivi Sahlberg
Journal:  Sci Rep       Date:  2021-05-25       Impact factor: 4.379

2.  MiR-7 Functions as a Tumor Suppressor by Targeting the Oncogenes TAL1 in T-Cell Acute Lymphoblastic Leukemia.

Authors:  Hongbo Sun; Zhifu Zhang; Wei Luo; Junmin Liu; Ye Lou; Shengmei Xia
Journal:  Technol Cancer Res Treat       Date:  2020 Jan-Dec

3.  Inhibition of Skp2 Sensitizes Chronic Myeloid Leukemia Cells to Imatinib.

Authors:  Xiaowen Chen; Zhenqi Huang; Wei Wu; Ruixiang Xia
Journal:  Cancer Manag Res       Date:  2020-06-22       Impact factor: 3.989

4.  LncRNA ANRIL/miR-7-5p/TCF4 axis contributes to the progression of T cell acute lymphoblastic leukemia.

Authors:  Gang Li; Lan Gao; Jing Zhao; Dejun Liu; Hui Li; Min Hu
Journal:  Cancer Cell Int       Date:  2020-07-23       Impact factor: 5.722

Review 5.  MicroRNAs in Autoimmunity and Hematological Malignancies.

Authors:  Mirco Di Marco; Alice Ramassone; Sara Pagotto; Eleni Anastasiadou; Angelo Veronese; Rosa Visone
Journal:  Int J Mol Sci       Date:  2018-10-12       Impact factor: 5.923

Review 6.  The Network of Non-coding RNAs in Cancer Drug Resistance.

Authors:  Fabio Corrà; Chiara Agnoletto; Linda Minotti; Federica Baldassari; Stefano Volinia
Journal:  Front Oncol       Date:  2018-08-29       Impact factor: 6.244

Review 7.  PI3 kinase signaling pathway in hematopoietic cancers: A glance in miRNA's role.

Authors:  Elham Roshandel; Leila Noorazar; Behrouz Farhadihosseinabadi; Mahshid Mehdizadeh; Mohammad Hossein Kazemi; Sayeh Parkhideh
Journal:  J Clin Lab Anal       Date:  2021-03-05       Impact factor: 2.352

8.  miR-101-5p Acts as a Tumor Suppressor in HER2-Positive Breast Cancer Cells and Improves Targeted Therapy.

Authors:  Lisa Svartdal Normann; Mads Haugland Haugen; Miriam Ragle Aure; Vessela N Kristensen; Gunhild Mari Mælandsmo; Kristine Kleivi Sahlberg
Journal:  Breast Cancer (Dove Med Press)       Date:  2022-03-01

Review 9.  MiR-7 in Cancer Development.

Authors:  Petra Korać; Mariastefania Antica; Maja Matulić
Journal:  Biomedicines       Date:  2021-03-23

Review 10.  Role of PI3K/AKT pathway in cancer: the framework of malignant behavior.

Authors:  Ningni Jiang; Qijie Dai; Xiaorui Su; Jianjiang Fu; Xuancheng Feng; Juan Peng
Journal:  Mol Biol Rep       Date:  2020-04-24       Impact factor: 2.742

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.